Download BMBF - pdpfundersgroup.org

Updated August 2014
FEDERAL MINISTRY OF EDUCATION AND RESEARCH (BMBF)
GERMANY
Overview
Type of funder
Government
Key contacts for PDP
related issues
Contacts at KfW:
Andrea Holzäpfel ([email protected])
Arlina Elmiger ([email protected])
PDPs currently funded
 Drugs for Neglected Diseases Initiative (DNDi)
 European Vaccine Initiative (EVI)
 Foundation for Innovative New Diagnostics (FIND)
 Dengue Vaccine Initiative (DVI)
PDPs no longer
funded
Management of PDPs
Funding comes from BMBF and is administered by KfW.
Funding is managed through agreements with the individual PDPs.
Key PDP related
documents
Research funding concept: Neglected and poverty-related diseases.
2011.
http://www.bmbf.de/en/15337.php?hilite=PDP
(e.g., strategy
documents,
documents justifying
funding for PDPs, PDP
evaluations)
Other activities being
funded that support
the work of PDPs (for
example, support for
early stage
development projects,
policy studies, funding
for clinical trial
platforms (eg. EDCTP)
BMBF also provides
- basic research, preclinical and clinical phase funding in
Germany
- support for EDCTP for clinical-phase research on
HIV/AIDS, malaria and tuberculosis
- funding for health research in Africa to improve healthcare
systems
For details see:
http://www.bmbf.de/pubRD/neglected_poverty_related_diseases.pdf
Updated August 2014
A. DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI)
BMBF Awards to DNDi as of October 2012
DNDi-1
Grant of €8 million over four years starting in 2011
Details of the latest grant (DNDi-1)
Amount
€ 8 million
Grant period
01 Dec 2011 – 30 Nov 2015
Funding Department
BMBF
Scope of activities funded
Project funding for the development of new treatments to
support control and elimination of human African
trypanosomias (HAT), visceral leishmaniasis (VL),
Chagas disease and helminth infections.
Restrictions on use of funds
At least 50% of the total funding for the product under
development must be obtained from other sources. Costs
for lobbying, public relations, general networking
activities, and taxes are non-eligible costs.
Reporting requirements
- Annual scientific progress reports: in the format agreed
by the PDP Funders Group as well as project-specific
report.
- Annual project-specific financial audit reports as well as
review of the standard annual financial statements.
Evaluation requirements
None specified.
Contact
Nina Holzhauer (Policy and Development Coordinator)
Bernard Pecoul (Executive Director)
Updated August 2014
B. EUROPEAN VACCINE INITIATIVE (EVI)
BMBF Awards to EVI as of October 2012
EVI -1
Grant of € 4.432.025 over four years starting in 2011
Details of the latest grant (EVI-1)
Amount
€ 4.432.025
Grant period
01 Dec 2011 – 30 Nov 2015
Funding Department
BMBF
Scope of activities funded
Project funding for the further development of a vaccine
specific to pregnancy associated malaria (PAM).
Restrictions on use of funds
At least 50% of the total funding for the product under
development must be obtained from other sources. Costs
for lobbying, public relations, general networking
activities, and taxes are non-eligible costs.
Reporting requirements
- Annual scientific progress reports: in the format agreed
by the PDP Funders Group as well as project-specific
annual scientific progress reports.
- Annual project-specific financial audit reports as well as
review of the standard annual financial statements.
Evaluation requirements
None specified.
Contact
Dr. Odile Leroy (Executive Director)
Updated August 2014
C. FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS (FIND)
BMBF Awards to FIND as of October 2012
FIND-1
Grant of € 7.450.800 over four years starting in 2011
Details of the latest grant (FIND-1)
Amount
€ 7.450.800
Grant period
01 Dec 2011 – 30 Nov 2015
Funding Department
BMBF
Scope of activities funded
Project funding for the development of a molecular
platform for the detection of parasitic diseases (Chagas
disease, leishmaniasis, human African trypanosomias
(HAT), and malaria) that is simple enough to be used in
low-resource settings.
Restrictions on use of funds
At least 50% of the total funding for the product under
development must be obtained from other sources. Costs
for lobbying, public relations, general networking
activities, and taxes are non-eligible costs.
Reporting requirements
- Annual scientific progress reports: in the format agreed
by the PDP Funders Group as well as project-specific
annual scientific progress reports.
- Annual project-specific financial audit reports as well as
review of the standard annual financial statements.
Evaluation requirements
None specified.
Contact
Mark Perkins (Executive Director)
Sharon Saacks (Project Manager)
Updated August 2014
D. DENGUE VACCINE INITIATIVE (DVI)
BMBF Awards to DVI as of November 2013
DVI -1
Grant of € 1.000.000 over one year starting in 2013
Details of the latest grant (DVI-1)
Amount
€ 1.000.000
Grant period
01 Nov 2013 – 31 Oct 2014
Funding Department
BMBF
Scope of activities funded
Restrictions on use of funds
Reporting requirements
Project funding to support two developing country vaccine
manufacturers in Brasil and Vietnam to accelerate the
development of a dengue vaccine and to ensure an
expanded supply at a low cost.
At least 50% of the total funding for the product under
development must be obtained from other sources. Costs
for lobbying, public relations, general networking
activities, prevention programmes, attendance of
conferences and events not focused on scientific areas or
product development and taxes are non-eligible costs.
- Interim progress meeting
- Final scientific progress report at the end of the project
- Project-specific financial audit report at the end of the
project.
Evaluation requirements
None specified.
Contact
Dr. Georges Thiry (Acting Director DVI)